Andrew J. Schwab, a director at Camp4 Therapeutics Corp (NASDAQ: CAMP), sold 10 common shares of the company for $4.50 per share on August 24, 2026, totaling $45.
Schwab serves as a managing member of the general partners for 5AM Ventures VI, L.P., 5AM Ventures VII, L.P., and 5AM Opportunities II, L.P., entities that hold substantial indirect stakes in Camp4 Therapeutics. These partnerships collectively own 5,677,216 shares of the company, though Schwab disclaims beneficial ownership beyond his pecuniary interest in the transaction.
The sale follows recent analyst activity that has highlighted Camp4 Therapeutics' pipeline and valuation potential. JPMorgan upgraded the stock from "Neutral" to "above average," citing the company's CMP-002 project and raising its price target to $9.00. Chardan initiated coverage with a "Buy" rating and set a price target of $6.50.
Kelly Gold, who serves as Chief Financial Officer of Camp4 Therapeutics and was recently appointed to X4 Pharmaceuticals' board of directors, oversees corporate finance, accounting, investor relations, and strategic financial planning for the company. Camp4 Therapeutics focuses on biotechnology advancements, particularly in antisense oligonucleotides.
